Understanding the Unicycive Lawsuit
Bragar Eagel & Squire, P.C., a well-known law firm, is currently managing a class action lawsuit against Unicycive Therapeutics, Inc. (NASDAQ: UNCY). They’re encouraging investors who have experienced losses in Unicycive shares to reach out and discuss their options as important deadlines approach.
Important Dates for Investors
For those who acquired Unicycive stock between March 29, 2024, and June 27, 2025, it's crucial to act fast. The firm is reminding all affected investors that they have until October 14 to apply to be appointed as lead plaintiff in this lawsuit. Missing this deadline may affect their ability to seek restitution.
What’s at Stake?
The allegations against Unicycive claim that the company misrepresented the readiness of its New Drug Application for oxylanthanum carbonate (OLC) intended for patients suffering from hyperphosphatemia, especially in chronic kidney disease cases requiring dialysis.
Key Allegations of the Lawsuit
The lawsuit asserts that Unicycive's disclosures inflated the potential of their application to secure FDA approval. Specifically, the firm argues that Unicycive failed to inform investors about significant manufacturing compliance issues identified by the FDA, leading to declines in their stock price.
Impact of Recent Announcements
On June 10, 2025, Unicycive publicly acknowledged that the FDA found compliance deficiencies with their third-party manufacturer. This announcement resulted in an immediate and steep decline in the stock price, with a subsequent update on June 30 causing an additional drop. Shareholders must be aware of these developments as they navigate the complexities of this situation.
Next Steps for Affected Investors
If you hold or have previously held Unicycive shares and have experienced losses due to the alleged misinformation, Bragar Eagel & Squire encourages you to connect with them. There's no cost attached to exploring your legal rights, and doing so promptly may help ensure you can participate in this class action effectively.
About Bragar Eagel & Squire, P.C.
This law firm stands out for its commitment to representing both individual and institutional investors in complex litigation cases across various jurisdictions. They possess extensive experience in securities-related matters, while consistently striving for investor rights.
Contact Information
For a no-obligation consultation, reach out to Bragar Eagel & Squire, P.C. directly at (212) 355-4648 or send an email to investigations@bespc.com. Detailed information can be found on their official website.
Frequently Asked Questions
What is the lawsuit about?
The lawsuit involves allegations that Unicycive misrepresented data regarding its New Drug Application readiness, affecting stock value.
When is the deadline for applying as lead plaintiff?
Investors have until October 14, 2025, to apply to be appointed as lead plaintiff.
What should I do if I lost money investing in Unicycive?
If you incurred losses, consider contacting Bragar Eagel & Squire to understand your legal options.
How can I stay informed about the lawsuit?
Ongoing updates can be tracked on Bragar Eagel & Squire's website and through their direct communications with clients.
Who can I contact for assistance?
Investors can reach out to Brandon Walker or Marion Passmore at the contact number provided for inquiries related to the case.
